Medpace (NASDAQ:MEDP) Given New $454.00 Price Target at Robert W. Baird

Medpace (NASDAQ:MEDP) had its price target boosted by Robert W. Baird from $446.00 to $454.00 in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has an outperform rating on the stock.

MEDP has been the topic of several other research reports. Jefferies Financial Group raised Medpace from a hold rating to a buy rating and upped their target price for the company from $340.00 to $450.00 in a research report on Tuesday. UBS Group raised Medpace from a neutral rating to a buy rating and increased their price target for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research report on Monday, March 18th. They set a hold rating and a $395.00 price target on the stock. Finally, StockNews.com raised Medpace from a hold rating to a buy rating in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $443.00.

Medpace Trading Down 2.4 %

Medpace stock opened at $397.56 on Wednesday. Medpace has a 12 month low of $189.30 and a 12 month high of $421.00. The stock’s 50 day moving average is $397.84 and its 200-day moving average is $323.66. The company has a market capitalization of $12.32 billion, a price-to-earnings ratio of 40.53, a PEG ratio of 2.04 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. During the same quarter in the prior year, the business earned $2.27 earnings per share. The firm’s revenue for the quarter was up 17.7% on a year-over-year basis. As a group, equities research analysts predict that Medpace will post 11.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Medpace news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The disclosure for this sale can be found here. Insiders sold 189,340 shares of company stock worth $76,651,647 over the last three months. Insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Arcadia Investment Management Corp MI raised its position in Medpace by 40.3% during the 1st quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 29 shares during the last quarter. Miller Howard Investments Inc. NY raised its position in Medpace by 1.3% during the 4th quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock worth $943,000 after purchasing an additional 39 shares during the last quarter. Schulhoff & Co. Inc. raised its position in Medpace by 2.0% during the 3rd quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company’s stock worth $545,000 after purchasing an additional 45 shares during the last quarter. Coldstream Capital Management Inc. raised its position in Medpace by 5.0% during the 4th quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock worth $292,000 after purchasing an additional 45 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Medpace by 43.3% during the 1st quarter. GAMMA Investing LLC now owns 149 shares of the company’s stock worth $60,000 after purchasing an additional 45 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.